- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07572006
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose [RP2D]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone and/or when administered in addition to standard of care (SoC) therapy at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system). For US sites: The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose [RP2D]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system).
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
-
Aarhus N, 덴마크, DK-8200
- 모병
- Aarhus University Hospital
-
Copenhagen, 덴마크, DK-2100
- 모병
- Rigshospitalet
-
-
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46237
- 모병
- Indiana Blood & Marrow Transplantation
-
-
Michigan
-
Grand Rapids, Michigan, 미국, 49546
- 모병
- Start Midwest
-
-
New Jersey
-
Piscataway, New Jersey, 미국, 08854
- 모병
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, 미국, 10016
- 모병
- NYU Langone Health
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Sarah Cannon Cancer Institute
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- MD Anderson Cancer Center - University of Texas
-
-
-
-
-
Edegem, 벨기에, 2650
- 모병
- UZ Antwerpen
-
Ghent, 벨기에, 9000
- 모병
- Ghent University Hospital
-
-
-
-
-
Madrid, 스페인, 28040
- 모병
- Hosp Univ Fund Jimenez Diaz
-
Pamplona, 스페인, 31008
- 모병
- Clinica Univ. de Navarra
-
-
-
-
-
Manchester, 영국, M20 4BX
- 모병
- The Christie Nhs Foundation Trust
-
-
-
-
-
Marseille, 프랑스, 13009
- 모병
- Institut Paoli Calmettes
-
Pierre-Bénite, 프랑스, 69495
- 모병
- CHU Lyon Sud
-
Toulouse, 프랑스, 31059
- 모병
- Institut Claudius Regaud
-
Tours, 프랑스, 37000
- 모병
- CHRU Tours Hopital Bretonneau
-
-
-
-
-
Concord, 호주, 2137
- 모병
- Concord Hospital
-
Melbourne, 호주, 3000
- 모병
- Peter MacCallum Cancer Centre
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
For Arm A:
- Have a diagnosis of: Acute myeloid leukemia (AML) per International Consensus Classification (ICC) 2022 or myelodysplastic syndromes (MDS) per world health organization (WHO) 2022 classified as moderate high, high, or very high-risk per the molecular international prognostic scoring system (IPSSM). All participants must have relapsed or refractory disease and have exhausted or are ineligible for standard therapeutic options
- Body weight greater than or equal to (>=) 40 kilograms (kg)
- Eastern cooperative oncology group (ECOG) performance status of 0 to 2
For Arm B:
-
All participants must have relapsed or refractory disease with no other approved therapies available that would be more appropriate in the investigator's judgement. Have a diagnosis of either: Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) meeting 2018 International workshop on chronic lymphocytic leukemia (iwCLL) National cancer institute (NCI) working group guidelines (Hallek 2018) that meet the following criteria:
a. Participants must have received at least 2 prior lines of therapy; b. Have clinically measurable disease
-
Body weight >= 40 kg
-
ECOG performance status of 0 to 2
-
Must sign an Informed consent form (ICF)
-
For US sites: Have a diagnosis of CLL/SLL that meets iwCLL, NCI Working Group Guidelines which is relapsed or refractory and requires treatment with no other approved therapies available that would be more appropriate in the investigator's judgement. a. Participants must have received at least 2 prior lines of therapy
Exclusion criteria:
For Arm A:
- Has acute promyelocytic leukemia according to world health organization (WHO) 2022 criteria or known active central nervous system (CNS) involvement of AML/MDS, unless in specific cohort (s) per study evaluation team (SET) decision
- Need for supplemental oxygen use to maintain adequate oxygenation
- Have evidence of uncontrolled systemic viral, bacterial, or fungal infection. Antimicrobial prophylaxis is permitted
- For US sites: Has acute promyelocytic leukemia according to WHO 2022 criteria or known active CNS involvement of AML/MDS
For Arm B:
- Need for supplemental oxygen use to maintain adequate oxygenation
- Have evidence of uncontrolled systemic viral, bacterial, or fungal infection requiring initiation of parenteral treatment as medical intervention
- Developed Richter's transformation or prolymphocytic leukemia
- Known active CNS or leptomeningeal involvement of CLL/SLL/Non-Hodgkin lymphoma (NHL)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm A: R/R Acute Myeloid Leukemia (AML)/ High-Risk Myelodysplastic Syndrome (HR MDS)
Participants with relapsed/refractory (R/R) AML/HR-MDS will receive JNJ-95804306 monotherapy (Arm A1) or as an addition to standard of care (SoC) therapy in AML (Arm A2) to determine the putative recommended phase 2 dose (RP2D) in Part 1 (Dose escalation) of the study. In Part 2 (Dose expansion) participants will receive JNJ-95804306 monotherapy (Arm A1) or as an addition to SoC therapy in AML (Arm A2) at the determined RP2D regimen(s). For US sites: Participants with R/R AML/HR-MDS will receive JNJ-95804306 monotherapy to determine the putative RP2D in Part 1 (Dose escalation) of the study. In Part 2 (Dose expansion) participants will receive JNJ-95804306 monotherapy at the determined RP2D regimen(s). AML SoC will not be administered for US sites. |
JNJ-95804306 will be administered orally. AML SoC will be administered subcutaneously/intravenously. |
|
실험적: Arm B: R/R Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) or NHL monotherapy
Participants with R/R CLL/SLL/NHL will receive JNJ-95804306 monotherapy (Arm B1) or as an addition to SoC therapy in R/R CLL/SLL (Arm B2 or B3) to determine the putative RP2D in Part 1 (Dose escalation) of the study. In Part 2 (Dose expansion) participants will receive JNJ-95804306 monotherapy (Arm B1) or as an addition to SoC therapy in R/R CLL/SLL (Arm B2 or B3) at the determined RP2D regimen(s). For US sites: Participants with R/R CLL/SLL/NHL will receive JNJ-95804306 monotherapy to determine the putative RP2D in Part 1 (Dose escalation) of the study. In Part 2 (Dose expansion) participants will receive JNJ-95804306 monotherapy at the determined RP2D regimen(s). CLL/SLL/NHL SoC will not be administered for US sites. |
JNJ-95804306 will be administered orally. CLL/SLL SoC will be administered orally/ intravenously. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
기간: Up to 28 days after first full dose of study drug
|
DLT is defined as any toxicity that requires discontinuation of treatment; any toxicity resulting in dose reduction of study treatment, any toxicity resulting in a participant receiving less than (<) 2/3 of their intended dose; any grade 5 toxicity; non-hematologic toxicity (grade 3 or 4); and unacceptable hematologic toxicity. |
Up to 28 days after first full dose of study drug
|
|
Number of Participants with Adverse Events (AEs) by Severity
기간: Up to 6 years 5 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 6.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to 6 years 5 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
For US sites: Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
기간: Up to first 28 days after first dose of study drug
|
DLT is defined as any toxicity that requires discontinuation of treatment; any toxicity resulting in dose reduction of study treatment, any toxicity resulting in a participant receiving less than (<) 2/3 of their intended dose; any grade 5 toxicity; non-hematologic toxicity (grade 3 or 4); and unacceptable hematologic toxicity. |
Up to first 28 days after first dose of study drug
|
|
Serum Concentrations of JNJ-95804306
기간: Up to approximately 6 years 5 months
|
Serum samples will be analyzed to determine concentrations of JNJ-95804306. |
Up to approximately 6 years 5 months
|
|
Area Under the Curve From Time of Administration until End of Dosing Interval (AUC[t]) of JNJ-95804306
기간: Up to approximately 6 years 5 months
|
AUC[t] is defined as the area under the plasma concentration time curve during a dosing interval at steady-state. |
Up to approximately 6 years 5 months
|
|
Maximum Plasma Concentration (Cmax) of JNJ-95804306
기간: Up to approximately 6 years 5 months
|
Cmax is defined as the maximum serum concentration of JNJ-95804306. |
Up to approximately 6 years 5 months
|
|
Minimum Plasma Concentration (Cmin) of JNJ-95804306
기간: Up to approximately 6 years 5 months
|
Cmin is defined as the minimum plasma concentration of JNJ-95804306. |
Up to approximately 6 years 5 months
|
|
Complete Response (CR) in Participants with Acute Myeloid Leukemia (AML)
기간: Up to 6 years 5 months
|
Complete response (CR) is achieved when a participant with AML has a best response of CR (complete response with partial hematologic recovery [CRh] or complete response with incomplete hematologic recovery [CRi]) according to the European Leukemia Network (ELN) 2022 criteria. |
Up to 6 years 5 months
|
|
Overall Response (OR) in Participants with Myelodysplastic Syndrome (MDS)
기간: Up to 6 years 5 months
|
OR is achieved when a participant with MDS has a CR (any type, that is CRh or complete response with limited count recovery [CRL]), partial response (PR), or hematologic improvement (HI) according to the International Working Group (IWG) 2023 criteria. |
Up to 6 years 5 months
|
|
Complete Response (CR) in Participants with MDS
기간: Up to 6 years 5 months
|
CR is achieved when a participant with MDS has a best response of CR (including CRh/CRL) according to the IWG 2023 criteria. |
Up to 6 years 5 months
|
|
Overall Response (OR) in Participants with Chronic Lymphocytic Leukemia (CLL)
기간: Up to 6 years 5 months
|
OR is achieved when a participant with CLL has a CR or PR according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. |
Up to 6 years 5 months
|
|
Complete Response in Participants with CLL
기간: Up to 6 years 5 months
|
Complete response as per iwCLL response criteria will be reported. |
Up to 6 years 5 months
|
|
Overall Response in Participants with Non-Hodgkin Lymphoma (NHL) Subtypes Including Small Lymphocytic Lymphoma (SLL)
기간: Up to 6 years 5 months
|
Overall response is achieved when a participant with NHL subtypes including SLL has a CR or PR according to the revised response criteria for malignant lymphoma. |
Up to 6 years 5 months
|
|
Complete Response in Participants With NHL Subtypes Including SLL
기간: Up to 6 years 5 months
|
Complete response is achieved when a participant with NHL subtypes including SLL has a best response of CR according to the revised response criteria for malignant lymphoma. |
Up to 6 years 5 months
|
|
Overall Response in WM (Waldenstrom's Macroglobulinemia)
기간: Up to 6 years 5 months
|
Overall response is achieved when a participant with WM has a CR or PR according to international workshop on waldenstrom's macroglobulinemia 2013 |
Up to 6 years 5 months
|
|
Complete Response in WM
기간: Up to 6 years 5 months
|
Complete response is achieved when a participant with WM has a best response of CR according to international workshop on waldenstrom's macroglobulinemia 2013. |
Up to 6 years 5 months
|
|
Best Overall Response (BOR) Based on Indication-Specific Criteria
기간: Up to 6 years 5 months
|
Participants with BOR based on indication-specific criteria will be reported. |
Up to 6 years 5 months
|
|
Duration of Response (DoR)
기간: Up to 6 years 5 months
|
DOR is defined for responders only, as time from date of initial documentation of a response to the first documented evidence of no response, disease progression, relapse, initiation of a new systemic anti-cancer therapy (besides hematopoietic stem cell transplant [HSCT]), or death, whichever comes first. |
Up to 6 years 5 months
|
|
Time to Response (TTR)
기간: Up to 6 years 5 months
|
TTR is defined for responders only, as the time from the first dose of any study treatment to first qualifying response. |
Up to 6 years 5 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 95804306EDI1001
- 95804306EDI1001 (기타 식별자: Janssen Research & Development, LLC)
- 2026-525234-39 (EudraCT 번호)
- 2026-525234-39-00 (레지스트리 식별자: EUCT number)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .